Trending Articles

article thumbnail

Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case

Fierce Pharma

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular Type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said.

Pharma 308
article thumbnail

The 2024 PharmaVoice 100

PharmaVoice

This year’s PharmaVoice 100 encompasses the industry’s ongoing revolutions and leaders who are not only navigating these changes, but at times, forging new paths for others to follow.

97
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

US' top IV fluid maker Baxter voices uncertainty about recovery timeline at NC facility hit by Helene

Fierce Pharma

After announcing the closure of its biggest manufacturing site Sunday due to flooding caused by Hurricane Helene, Baxter International—the U.S.’ top supplier of hospital IV fluids—is laying out det | While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.

article thumbnail

First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic 

MedCity News

The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority. The post First Do No Harm: Support Legislative Efforts to Combat the Adverse Drug Event Epidemic appeared first on MedCity News.

Medical 121
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

FDA approval give BMS an edge in NSCLC treatment

pharmaphorum

Bristol Myers Squibb (BMS) has been granted approval by the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC).

article thumbnail

NUHS’s CD7 CAR-T cell therapy shows promise for leukaemia

Pharmaceutical Technology

The CD7 CAR)-T cell therapy has demonstrated potential in treating patients with relapsed or refractory T-cell leukaemia.

Patients 117

More Trending

article thumbnail

First real-world study reveals encouraging efficacy for cell therapy

European Pharmaceutical Review

New results from a first-of-its-kind study reports that a CAR-T cell therapy provided similar efficacy and safety to relapsed or refractory multiple myeloma patients administered with the treatment in clinical trials. For example, of the 236 patients who received infusions of ciltacabtagene autoleucel (cilta-cel), data shows that 89 percent responded to the treatment.

article thumbnail

Gilead strikes deal to expand HIV drug access in 120 countries

pharmaphorum

Gilead has partnered with six generic manufacturers to expand access to HIV Drug lenacapavir in high-incidence, resource-limited countries following promising clinical trial results.

article thumbnail

Novo’s GLP-1 Wegovy could improve heart health for millions more than previously thought, AI study finds

PharmaVoice

Through real-world data, an AI company found that popular weight loss drugs could be a preventive measure for patients at risk of heart attack and stroke.

article thumbnail

Gilead strikes licensing deals with 6 generics makers to boost access to long-acting HIV PrEP med

Fierce Pharma

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV candidate lenacapavir. | The company will allow six generic manufacturers to make and sell its long-acting PrEP drug, lenacapivir, in 120 resource-limited countries.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Funding In Youth Mental Health Is Growing. Where are the Opportunities?

MedCity News

More investors are becoming interested in digital health startups specifically targeting youth behavioral health. However, there are still more opportunities to reach youth on Medicaid. The post Funding In Youth Mental Health Is Growing. Where are the Opportunities? appeared first on MedCity News.

123
123
article thumbnail

Enhancing intestinal drug delivery with Quality by Design

European Pharmaceutical Review

A study has reported an approach for optimising metronidazole colonic delivery systems, to increase their potential efficacy when treating diverticulitis. Researchers developed intestinal colon-coated sustained-release matrix metronidazole tablets, using a Quality by Design (QbD) approach. Arévalo-Pérez et al. noted that metronidazole is a synthetic nitroimidazole and has activity against anaerobic bacteria.

article thumbnail

NHS England to be given a bigger role in GP data sharing

pharmaphorum

UK Health Secretary Wes Streeting has announced plans to allow NHS England to share primary care data with scientific researchers, taking on some of the responsibility held by GPs. The minister told the Royal College of General Practitioners (RCGP) annual conference that, while many UK patients have given their consent for their data to be shared with studies run by the likes of the UK Biobank, Genomics England, and Our Future Health, they "still see, far too often, that this data is not shared

Patients 107
article thumbnail

AAPS PharmSci 360 2024: Drug Delivery in Early Development

PharmaTech

Pharmaceutical Technology sat down with Erica Schlesinger, vice president of technical development at Serán Bioscience, to talk about her upcoming presentation at AAPS PharmSci 360 2024, “High Dose Subcutaneous Delivery of Protein Therapeutics.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

J&J's Erleada prevails over Astellas, Pfizer’s Xtandi in real-world prostate cancer study

Fierce Pharma

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi has held a larger slice of the market than Johnson & Johnson’s riva | A real-world, head-to-head study of two androgen receptor pathway inhibiting (ARPI) prostate cancer drugs indicates that Johnson & Johnson’s Erleada provides an edge in overall survival versus Astellas and Pfizer’s Xtandi.

Marketing 323
article thumbnail

SCAN, Astrana Launch MA Plan Tailored to Asian Older Adults

MedCity News

SCAN Health Plan and Astrana Health recently launched SCAN Allied, a Medicare Advantage plan designed for the Asian older adult population. It includes access to a network of culturally competent providers, specialists and pharmacies from Astrana Health. The post SCAN, Astrana Launch MA Plan Tailored to Asian Older Adults appeared first on MedCity News.

article thumbnail

Social media algorithms are driving the GLP-1 drugs boom

Pharmaceutical Technology

GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.

Media 105
article thumbnail

Amgen to face investor lawsuit over $10.7bn tax liability disclosure

pharmaphorum

A federal judge in New York has ruled that Amgen must answer to claims of misleading investors about billions owed to US tax authorities, allowing a securities-fraud class action to proceed against the pharmaceutical giant.

article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

KOL Collaboration Series: Expanding Pharmacies’ Scope of Practice

Pharmaceutical Commerce

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenni Zilka, SVP, community & specialty pharmacy and president, Good Neighbor Pharmacy, explains how pending legislation can improve patient access, and how these are helping with recognizing pharmacists as HCPs.

Pharma 59
article thumbnail

Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility

Fierce Pharma

Aspen Neuroscience, underway with Parkinson's cell therapy trial, bolsters manufacturing with new San Diego facility fkansteiner Wed, 10/02/2024 - 07:31

article thumbnail

How A Physician Group Is Using AI to Save Clinicians 3+ Hours Per Day on Documentation

MedCity News

Alpine Physician Partners — which operates primary care organizations in several states — is implementing Ambience Healthcare’s documentation and coding tool after a successful pilot. Before adopting Ambience’s tool, Alpine clinicians spent 4.7 hours on charting per day, but now that time has dropped down to 1.2 hours per day. The post How A Physician Group Is Using AI to Save Clinicians 3+ Hours Per Day on Documentation appeared first on MedCity News.

article thumbnail

LoQus23 secures $43m to advance Huntington’s Disease therapy

Pharmaceutical Technology

The funds will support the development of LoQus23’s lead candidate, its MutSβ inhibitor, as it enters clinical development.

Leads 105
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Blue Shield of California bypasses PBMs to slash Humira prices by 90%

pharmaphorum

In a bold move to tackle soaring drug costs, Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the cost of Humira by 90%

article thumbnail

Building Rapport In Sales Is An Essential Selling Skill – Here’s Why

Integrity Solutions

Building rapport in sales is essential for establishing trust and fostering long-term relationships with clients. While technology has made it easier than ever for buyers to access information, B2B buyers in particular are looking for insights and advice from a salesperson they can trust and who they believe has their best interests in mind to help them make good decisions.

Sales 54
article thumbnail

Amgen can't sidestep investor lawsuit over $10.7B tax bill

Fierce Pharma

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IR | New York District Judge John Cronan has rejected Amgen’s motion to dismiss an investor lawsuit—originally filed by a Michigan-based union pension fund—accusing the company of hiding a $10.7-billion tax bill from the public.

319
319
article thumbnail

J&J Backs Down From 340B Rebates, But Maintains They’re ‘Legally Permissible’ Per Statute

MedCity News

Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In other recent regulatory news, we have drug approvals, clinical holds, and one product withdrawal. The post J&J Backs Down From 340B Rebates, But Maintains They’re ‘Legally Permissible’ Per Statute appeared first on MedCity News.

Biopharma 114
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

article thumbnail

Social media algorithms are driving the the GLP-1 drugs boom

Pharmaceutical Technology

GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might be.

Media 98
article thumbnail

AI pathology accelerates with Proscia Concentriq launch

pharmaphorum

Proscia announces launch of Concentriq Embeddings and Proscia AI Toolkit, hoping to accelerate precision medicine R&D.

Medicine 109
article thumbnail

CPHI Milan 2024: Flavonoids in Pharmaceuticals

PharmaTech

Pharmaceutical Technology® Europe sat down with Álvaro Nocete Díaz, Pharma Division Manager at HTBA, about the benefits of flavonoids and their use in the pharmaceutical industry.

article thumbnail

Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs

Fierce Pharma

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, | Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time